CSTL · Castle Biosciences Inc
$24.55
+0.66 (+2.76%)
At close · Jul 29
Market Cap
$724.58M
Shares
30.33M
Castle Biosciences Inc Earnings Call Transcripts
Every quarterly earnings call for Castle Biosciences Inc (CSTL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲57.7%
$37.01M
−$20.25M
'22 Q3
22-11-02
▲53.1%
$38.34M
−$20.62M
'22 Q4
23-01-09
▲56.6%
$42.04M
−$29.20M
'23 Q1
23-05-03
▲43.9%
$50.14M
−$18.78M
'23 Q2
23-08-02
▲66.1%
$61.49M
−$6.91M
'23 Q3
23-11-02
▲72.5%
$66.12M
−$2.58M
'23 Q4
24-02-28
▲73.6%
$72.97M
−$2.53M
'24 Q1
24-05-02
▲73.5%
$87.00M
$8.92M
'24 Q2
24-08-05
▲39.5%
$85.78M
$2.27M
'24 Q3
24-11-04
▲30.5%
$86.31M
$9.59M
'24 Q4
25-02-27
▲20.6%
$87.99M
−$25.85M
'25 Q1
25-05-05
▼0.9%
$86.19M
$4.52M
'25 Q2
25-08-04
▼3.2%
$83.04M
−$501,000
'25 Q3
25-11-03
▲0.8%
$87.01M
−$2.33M
'25 Q4
26-01-13
LATEST
▼4.9%
$83.68M
−$14.52M
'26 Q1
26-05-06
Earnings call
FY26 · Q2
2026-07-30
Castle Biosciences Q2 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Castle Biosciences Inc Q1 FY2026 Earnings Call
Confident tone
Revenue growth and guidance raise
FDA submission timeline for melanoma test
Advanced ADTx (atopic dermatitis) ramp
Revenue
$83.68M
▼ 4.9% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-01-13
Castle Biosciences Inc Q4 FY2025 Earnings Call
Confident tone
Financial performance and 2026 outlook
TissueCypher growth in gastroenterology
DecisionDx-Melanoma performance and adoption
Revenue
$87.01M*
▲ 0.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Castle Biosciences Inc Q3 FY2025 Earnings Call
Confident tone
AdvanceAD-Tx launch in atopic dermatitis
Q3 financial performance
TissueCypher (Barrett's esophagus) growth
Revenue
$83.04M
▼ 3.2% YoY Diluted EPS
$-0.02
▼ 125% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Castle Biosciences Inc Q2 FY2025 Earnings Call
Confident tone
DecisionDx-SCC reimbursement and Novitas LCD
Pipeline and M&A (SciBase and Previse)
DecisionDx-Melanoma performance and growth
Revenue
$86.19M
▼ 0.9% YoY Diluted EPS
$0.15
▼ 51.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Castle Biosciences Inc Q1 FY2025 Earnings Call
Confident tone
Previse Acquisition / GI Pipeline
Financial Performance
DecisionDx-Melanoma
Revenue
$87.99M
▲ 20.6% YoY Diluted EPS
$-0.90
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Castle Biosciences Inc Q4 FY2024 Earnings Call
Balanced tone
DecisionDx-SCC reimbursement and Novitas LCD risk
DecisionDx-Melanoma volume and penetration
Balance sheet and financial strength
Revenue
$86.31M*
▲ 30.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Castle Biosciences Inc Q3 FY2024 Earnings Call
Confident tone
Novitas Medicare Reimbursement Review for SCC
DecisionDx-Melanoma Performance and Evidence
DecisionDx-SCC Test Momentum
Revenue
$85.78M
▲ 39.5% YoY Diluted EPS
$0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Castle Biosciences Inc Q2 FY2024 Earnings Call
Confident tone
DecisionDX-SCC growth and ART utility
DecisionDX-Melanoma performance and clinical evidence
Commercial payer coverage dynamics
Revenue
$87.00M
▲ 73.5% YoY Diluted EPS
$0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Castle Biosciences Inc Q1 FY2024 Earnings Call
Confident tone
Clinical evidence and publications
TissueCypher Barrett's esophagus test
MolDX LCD process for SCC
Revenue
$72.97M
▲ 73.6% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Castle Biosciences Inc Q4 FY2023 Earnings Call
Confident tone
Revenue and volume growth
DecisionDx-SCC adoption and growth
DecisionDx-melanoma clinical evidence
Revenue
$66.12M*
▲ 72.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Castle Biosciences Inc Q3 FY2023 Earnings Call
Revenue
$61.49M
▲ 66.1% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Castle Biosciences Inc Q2 FY2023 Earnings Call
Revenue
$50.14M
▲ 43.9% YoY Diluted EPS
$-0.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Castle Biosciences Inc Q1 FY2023 Earnings Call
Revenue
$42.04M
▲ 56.6% YoY Diluted EPS
$-1.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Castle Biosciences Inc Q4 FY2022 Earnings Call
Revenue
$38.34M*
▲ 53.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Castle Biosciences Inc Q3 FY2022 Earnings Call
Revenue
$37.01M
▲ 57.7% YoY Diluted EPS
$-0.77
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Castle Biosciences Inc Q2 FY2022 Earnings Call
Revenue
$34.84M
▲ 53.1% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Castle Biosciences Inc Q1 FY2022 Earnings Call
Revenue
$26.85M
▲ 17.7% YoY Diluted EPS
$-0.97
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Castle Biosciences Inc Q4 FY2021 Earnings Call
Revenue
$25.04M*
▲ 44.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Castle Biosciences Inc Q3 FY2021 Earnings Call
Revenue
$23.48M
▲ 54.3% YoY Diluted EPS
$-0.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Castle Biosciences Inc Q2 FY2021 Earnings Call
Revenue
$22.76M
▲ 79% YoY Diluted EPS
$-0.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Castle Biosciences Inc Q1 FY2021 Earnings Call
Revenue
$22.81M
▲ 31% YoY Diluted EPS
$-0.17
▼ 666.7% YoY Gross margin
86.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-08
Castle Biosciences Inc Q4 FY2020 Earnings Call
Revenue
$17.30M
▼ 1.9% YoY Diluted EPS
$-0.23
▼ 309.1% YoY Gross margin
84.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Castle Biosciences Inc Q3 FY2020 Earnings Call
Revenue
$15.22M
▲ 3% YoY Diluted EPS
$-0.23
▼ 560% YoY Gross margin
83.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Castle Biosciences Inc Q2 FY2020 Earnings Call
Revenue
$12.71M
▲ 18.4% YoY Diluted EPS
$-0.08
Gross margin
83.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Castle Biosciences Inc Q1 FY2020 Earnings Call
Revenue
$17.42M
▲ 99.8% YoY Diluted EPS
$0.03
Gross margin
86.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-09
Castle Biosciences Inc Q4 FY2019 Earnings Call
Revenue
$17.64M
▲ 54.2% YoY Diluted EPS
$0.11
▼ 71.1% YoY Gross margin
88.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1447362
CUSIP
14843C105
13F (30d)
28 filings
28 filers
Visit website
Investor relations